retatrutide safety clinical trial 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Retatrutide Research Concentration Overview |
Description
There is no recommended dose because retatrutide is not yet FDA approved
3 month supply
Bucinskaite V, Tolessa T, Pedersen J, et al
Arch Ital Biol 2010;148:107-118
Of interest, blood glucose levels can increase in the short-term post-cessation, while reductions in A1C and mortality are benefits in the long-term
If dizziness persists despite appropriate management strategies, further investigation may be warranted to exclude other causes unrelated to the medication itself
